诱导治疗后123I-MIBG SPECT/CT半定量评分对儿童4期高危神经母细胞瘤的预后价值
该回顾性研究纳入116例接受诱导治疗的4期高危神经母细胞瘤患儿,评估123I-MIBG SPECT/CT的Curie评分与预后关系。Curie评分>6是独立不良预后因素,且与MYCN扩增协同提示更差结局。
要点
- 诱导治疗后Curie评分>6与更低的PFS和OS显著相关。
- Curie评分>6、神经母细胞瘤病理、MYCN扩增和11q23异常是独立不良预后因素。
- MYCN扩增患者中Curie评分>6与更差临床结局显著相关。
核心结论
- 诱导治疗后123I-MIBG SPECT/CT的Curie评分与MIBG阳性4期高危神经母细胞瘤患儿预后强相关。
研究设计与样本
- 回顾性分析116例接受诱导治疗的4期高危神经母细胞瘤患儿,均行123I-MIBG SPECT/CT并评估Curie评分。
主要发现
- Curie评分>6组(n=29)1年PFS为55.2%±9.2%,≤6组(n=87)为79.3%±4.3%;3年PFS分别为15.1%±8.3%与54.7%±5.9%(P<0.001)。
- Curie评分>6组1年OS为70.0%±18.2%,≤6组为89.9%±5.6%;3年OS分别为0.0%与60.0%±11.8%(P=0.002)。
- 多因素Cox回归显示Curie评分>6、神经母细胞瘤病理、MYCN扩增和11q23异常为独立不良预后预测因素。
- 在MYCN扩增的神经母细胞瘤患者中,Curie评分>6与更差临床结局显著相关。
关键数值与推荐
- 通过约登指数确定诱导治疗后Curie评分最佳截断值为6。
临床怎么用
- 诱导治疗后Curie评分≤6的患儿可能从后续巩固和维持治疗策略中获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to evaluate the prognostic significance of a semi-quantitative scoring system derived from 123 I-Metaiodobenzylguanidine ( 123 I-MIBG) SPECT/CT imaging in predicting clinical outcomes for pediatric patients with stage 4 high-risk neuroblastoma after induction therapy. METHODS: A retrospective analysis was conducted on a cohort of 116 pediatric patients diagnosed with stage 4 high-risk neuroblastoma. All patients received induction therapy and subsequently underwent 123 I-MIBG SPECT/CT imaging in our department. The Curie score and relevant clinical indicators were assessed, and both univariate and multivariate Cox proportional hazards models were applied to identify independent risk factors associated with disease recurrence. The optimal cutoff value for the Curie score was determined using the Youden index. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. RESULTS: According to the Youden index, the optimal cutoff value for Curie score after induction therapy was established as 6. Patients with a Curie score >6 (n=29) exhibited significantly lower PFS and OS compared with those with a Curie score≤6 (n=87). Specifically, 1-year PFS was 55.2%±9.2% versus 79.3%±4.3%, and 3-year PFS was 15.1%±8.3% versus 54.7%±5.9% ( P <0.001). Similarly, 1-year OS was 70.0%±18.2% versus 89.9%±5.6%, and 3-year OS was 0.0% versus 60.0%±11.8% ( P =0.002). Multivariate Cox regression analysis revealed that a Curie score >6, the presence of neuroblastoma pathology, MYCN amplification, and 11q23 aberration were independent predictors of poor prognosis. Among patients with MYCN-amplified neuroblastoma, a higher Curie score (>6) was significantly associated with worse clinical outcomes. CONCLUSIONS: This study demonstrates that the Curie score derived from 123 I-MIBG SPECT/CT imaging after induction therapy is strongly associated with the prognosis of pediatric patients with MIBG-avid stage 4 high-risk neuroblastoma. Notably, patients achieving a Curie score of 6 or lower after induction therapy may benefit from subsequent consolidation and maintenance treatment strategies.
引用
- Wang X, Wang G, Zhou Z, et al. Prognostic Value of a Semi-Quantitative Score Based on 123 I-MIBG SPECT/CT in Pediatric Patients With Stage 4 High-Risk Neuroblastoma After Induction Therapy. Clin Nucl Med. 2026. PMID: 41729085. doi:10.1097/RLU.0000000000006372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。